Interferons (IFNs) play an essential role in innate and adaptive immunity and the host defense system against viral, bacterial, and parasitic infections (49) . Also, IFNs have been used as therapeutic agents for treating human solid and hematologic malignancies, such as hairy cell leukemia, chronic myelogenous leukemia, follicular (non-Hodgkin's) lymphoma, and malignant melanoma (34, 81) . Although the mechanism of the IFNinduced antitumor activity is poorly understood, it is believed that the IFN-inducible proteins may be critical for executing tumor suppression (48) . Indeed, IFN-inducible genes, such as those for RNase L (73) , IFN regulatory factor 1 (67) , and the double-stranded RNA-regulated serine/threonine protein kinase (PKR) (39) , have been implicated in tumor suppression.
The IFN-inducible HIN-200 gene family encodes a class of proteins that share a 200-amino-acid (HIN) signature motif of type a and/or type b. Four human (IFI16, MNDA, AIM2, and IFIX) and five mouse (p202a, p202b, p203, p204, and p205 [or D3]) HIN-200 family proteins have been identified (2, 54) . genes are located at chromosome 1q21-23 as a gene cluster in both mouse and human genomes. Most HIN-200 proteins possess two major protein domains. First, the N-terminal region of HIN-200 proteins contains a highly helical pyrin domain (PYD) (36) , which belongs to the death domaincontaining protein superfamily involved in apoptosis and inflammation (52, 66, 75) . Second, the C-terminal HIN domain consists of two consecutive oligonucleotide/oligosaccharidebinding folds (1) . The oligonucleotide/oligosaccharide-binding fold-containing proteins are involved in a variety of biological processes, including DNA replication, DNA recombination, DNA repair, and telomere maintenance (6, 78) . However, the role of HIN-200 proteins in these biological processes is poorly understood.
The observations that HIN-200 proteins interact with several cellular regulators involved in cell cycle control, differentiation, and apoptosis suggest that the physiological role of proteins is beyond the IFN system (2, 54) . Moreover, the observation that HIN-200, e.g., IFI16, is widely expressed in normal human tissues, including endothelial and epithelial cells, further supports this notion (27, 65, 83) . Therefore, it is not surprising that loss or reduced expression of HIN-200 genes is associated with human cancers (3, 17-19, 26, 46, 61, 64, 80) . These studies suggest that HIN-200 proteins may play a role in tumor suppression.
The mouse double-minute gene 2 (mdm2) encodes an oncoprotein (22, 24) . Consistently, HDM2, the human homologue of mdm2, is found frequently overexpressed in human cancers, including about 50% of breast cancers (33, (55) (56) (57) 71) . A recent report also showed that HDM2 overexpression in tumors is associated with poor prognosis (59) . These results underscore the pivotal involvement of HDM2 in tumorigenesis. Therefore, HDM2 has been an important target for developing cancer therapeutics (25, 45, 72) .
The RING finger domain of HDM2 possesses an intrinsic E3 ubiquitin ligase activity (42) . Ubiquitinated proteins are targeted for proteasome-mediated degradation. The bestknown substrate of the E3 ligase activity of HDM2 is the p53 tumor suppressor protein. HDM2 binds to the N terminus of p53. This interaction allows HDM2 to inhibit p53 in two ways: (i) blocking the ability of p53 to activate transcription of its target genes by binding to the N-terminal transactivation domain of p53 (11, 62) and (ii) mediating ubiquitination of p53, leading to degradation by proteasome (30, 31, 47) . Interestingly, HDM2 is also a substrate of its own E3 ligase activity (23, 37) . The intricate regulation of p53 and HDM2 is further demonstrated by the fact that HDM2 is also p53 responsive (4, 63) . Thus, these two molecules link together in a negative feedback loop for the purpose of keeping the cellular p53 at low levels in the absence of stress. The p53-HDM2 autoregulatory loop is vital as demonstrated by the rescue of embryonic lethality of mdm2-null mice in a p53-null background (44, 60) . Therefore, a defective autoregulatory loop caused by mutations, DNA damage, or oncogenic insult has a profound impact on tumorigenesis (16) .
We recently identified IFIX as a novel member of the human HIN-200 family (18) . The IFIX transcriptional unit expresses at least six IFIX isoforms. IFIX proteins are primarily nuclear and possess a single type a HIN motif. Importantly, the expression of IFIX is reduced in the majority of breast tumors and breast cancer cell lines. Therefore, IFIX may function as a putative tumor suppressor. Consistently, the expression of IFIX␣1, the longest IFIX isoform, leads to suppression of growth and transformation in vitro and tumorigenicity and tumor growth in vivo (18) . The growth inhibitory activity of IFIX␣1 is associated with the induction of p21 CIP1 , a key cyclin-dependent kinase inhibitor (18) . However, the mechanism of the IFIX␣1 tumor suppressor activity has not been well elucidated. In this report, we show a novel interaction between IFIX␣1 and HDM2 which leads to destabilization of HDM2. Consequently, p53 is stabilized and activated. The novel cross talk between the IFN-IFIX signaling pathway and the HDM2-p53 autoregulatory loop may contribute in part to the IFNinduced antitumor activity in certain cancers.
MATERIALS AND METHODS
Cell lines, plasmids, and reagents. MCF-7 and its FLAG-tagged IFIX␣1 derivatives, X-1 and X-2, as well as MDA-MB-468 and its FLAG-tagged IFIX␣1 derivatives, X-1 and X-2, have been described previously (18) . The corresponding control cell lines are the pooled stable clones transfected with the empty vector (pCMV-Tag2B [FLAG]; Stratagene, La Jolla, CA) (18) . H1299, HCT116 and its p53-null derivative, HCT116 (p53 Ϫ/Ϫ ) (8), 293 and its large-T derivative, 293T, and p53 Ϫ/Ϫ and p53 Ϫ/Ϫ mdm2 Ϫ/Ϫ double-knockout (DKO) mouse embryonic fibroblasts (MEFs) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Raji cells treated with or without IFN-␣ (2,000 U/ml) and IFN-␥ (1,000 U/ml) (Sigma, St. Louis, MO), respectively, were grown in RPMI medium containing 10% or 0.2% FCS for the time indicated in the figure legends. MG132 (10 M) (Sigma) treatment was performed for 5 to 6 h prior to harvest. The enhanced green fluorescent protein (EGFP)-tagged IFIX␣1 (EGFP-IFIX␣1) and IFIX␤1 (EGFP-IFIX␤1) have been previously described (18) . The IFIX-N was generated using PCR primer set 5Ј-CCGGATCCTTAGAGATGGCAAATAACTAC (forward; containing a BamHI site) and 5Ј-CGGGATCCCTCAGTTGAGGAAGTGTTGG (reverse; containing a BamHI site) to amplify a 579-bp region corresponding to amino acids 1 to 193 of IFIX␣1. The IFIX-HIN was generated using PCR primer set 5Ј-CGGAATTCCAGACCTCATCATCAGCTCC (forward; containing an EcoRI site) and 5Ј-CGGGATCCTTACTGGATGAAACTATGCATTTC (reverse; containing a BamHI site) to amplify a 654-bp region corresponding to amino acids 179 to 397 of IFIX␣1. Both FLAG-tagged or EGFP-tagged IFIX-N and IFIX-HIN were generated as described before (18) . GFP-p53 (gift from G. Wahl) (76) , CMV-HDM2 (gift from Y. Zhang) (40) , and the HDM2 mutants, i.e., HDM2(⌬150-230) and HDM2(1-441), have been previously described (41 Fig. 8 are from a mixture of four IFIX siRNAs corresponding to amino acid sequences 689 to 707, 1,190 to 1,209, 1,246 to 1,265, and 1,486 to 1,504 of IFIX␣1 cDNA (Dharmacon). The nonspecific control siRNA is 5Ј-TAGCGACTAAACACATCAATT(dT)-3Ј (Dharmacon). Briefly, cells were suspended in the electroporation buffer (120 nM KCl, 0.15 mM CaCl 2 , 10 mM K 2 HPO 4 , 6 mM glucose, 25 mM HEPES [pH 7.6], 2 mM EGTA, and 5 mM MgCl 2 ). The siRNAs (100 nM) were then added to the cell suspension, followed by electroporation using Nucleofector (Amaxa Biosystems, Koeln, Germany).
Coimmunoprecipitation, Western blotting, and antibodies. Protein lysates (0.5 to 1.5 g) were prepared using radioimmunoprecipitation assay B lysis buffer as described previously (84) . The following antibodies (2 to 4 mg) were used in coimmunoprecipitation (co-IP): anti-HDM2 (D-7 for IP; and D-7 and N-20 for Western blotting [WB] ; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-FLAG (Sigma, M2 for co-IP and M5 for WB), and anti-GFP (Santa Cruz Biotech). Immune complexes were recovered using 30 l of protein G (for monoclonal antibodies) or protein A (for rabbit polyclonal antibodies) agarose (Roche) overnight at 4°C. Immune complex was then washed with phosphatebuffered saline four to six times at 4°C, followed by centrifugation and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Proteins were then transferred to a nitrocellulose membrane and probed with antibodies as indicated in the figure legends. Other antibodies used in the WB include antiprocyclic acidic repetitive protein (BD Biosciences, Palo Alto, CA), anti-␣-tubulin (Sigma), anti-PKR (Santa Cruz Biotech.), anti-IFI16 (Santa Cruz Biotech), anti-p53 (NeoMarker, Fremont, CA), and anti-p21 CIP1 (Santa Cruz Biotech). The peptide-purified anti-IFIX antibodies (recognizing ␣, ␤, and ␥ isoforms) are rabbit polyclonal antibodies against two overlapping peptides that correspond to the sequence 195 LKPLANRHATASKNIFREDPIIA 217 in the Nterminal domain of IFIX␣1 (Bethyl Laboratories, Inc., Montgomery, TX) (18) . The peptide-purified anti-IFIX␣ antibodies (recognizing ␣1 and ␣2 isoforms) are rabbit polyclonal antibodies against a synthetic peptide, 468 FRITSPTVAPPLSS DTSTNRHPAVP 492 , which corresponds to the C-terminal 25-amino-acid region of IFIX␣1 (18) (Bethyl Laboratories). Detection was achieved by incubating the secondary goat anti-rabbit or -mouse antibodies coupled with horseradish peroxidase (1:5,000) (Pierce), followed by use of the enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom).
Northern blot analysis. Northern blot analysis was performed as previously described (84) .
Luciferase assays. Cells transfected with the luciferase reporter gene, PG13-LUC (a firefly luciferase gene under the control of 13 p53 responsive elements) (79), MG15-LUC (a corresponding construct with mutated p53 responsive elements), and pRL-TK (for normalizing transfection efficiency) (Promega) were harvested to measure luciferase activity using the Dual-Luciferase reporter assay system (Promega, Madison, WI) and an illuminometer (TD-20/20; Promega).
Chromatin immunoprecipitation (ChIP) assay. The modified protocol was based on that previously published (53) . Briefly, IFIX␣1 stable MCF-7 cell lines and the vector control cell lines, X-1, X-2, and V, were fixed by 1% formaldehyde for 10 min before cell lysis. Cell lysates were subsequently sonicated, followed by centrifugation. The "input" (4% of the supernatant) was used in PCR as a positive control. The supernatant was then precleared using mouse immunoglobulin G (10 g) for 1 h at 4°C. Protein G-agarose beads (50 l) (Roche) were added to the supernatant and incubated for 2 h at 4°C. After centrifugation, the supernatant was then used for immunoprecipitation using anti-p53 antibody (2 g) (NeoMarker) or an irrelevant antibody, e.g., anti-GFP antibody (2 g) (Santa Cruz Biotech), and incubated overnight at 4°C. The protein/DNA complex was subsequently incubated with protein G-agarose beads for 2 h at 4°C. The immune complex was collected by centrifugation and then washed seven times with the following for 10 min each: twice with 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate; once with 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1% NP-40, and 0.1% SDS; twice with 50 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1% NP-40, 0.5% sodium deoxycholate, and 1 mM EDTA; and twice with TE [10 mM Tris-HCl, 1 mM EDTA] (pH 8.0) buffer. The immune complex was suspended in TE buffer with 0.25% SDS, protease K (250 g/ml), and RNase A (50 g/ml) (Sigma) and incubated at 37°C for 4 h and at 65°C overnight. The DNA was then extracted with phenol-chloroform and precipitated with ethanol in the presence of glycogen (20 g) as a carrier. The precipitate was used as a template for PCR amplification. The primers that specifically amplify a 320-bp region located approximately 0.7 to 1.0 kb upstream of the human p21 CIP1 promoter are 5Ј-AAACCATCTGCAAATGAGGG (forward) and 5Ј-GAACCAATCTCCCTACACC (reverse). PCR was performed under the following conditions: 35 cycles at 94°C for 40 seconds, 56°C for 1 min, and 72°C for 40 seconds.
Mobility shift assay. Nuclear extracts isolated from MCF-7 vector control, the IFIX␣1 stable cell lines (X-1 and X-2), and MCF-7 cells treated with or without UV light (20 J/m 2 ) were incubated with 32 P-labeled oligonucleotide containing p53 binding sites (p53 Nushift kit; Active Motif, Carlsbad, CA) in a binding reaction according to the manufacturer's instructions. The binding reaction was run on a 5% native polyacrylamide gel. Supershift assay was performed using the nuclear extract isolated from MCF-7 (X-1) cells incubated with or without the anti-p53 antibody provided by the p53 Nushift kit according to the manufacturer's protocol.
Cycloheximide-chase assay. Cells were cultured in six-well plates overnight. To measure the p53 turnover rate, MCF-7 vector control and the IFIX␣1 stable cell lines (X-1 and X-2) were treated with cycloheximide (CHX; 100 g/ml) (Sigma) for the indicated time, followed by Western blotting using anti-p53 antibody. To measure the turnover rate, H1299 cells were cotransfected with HDM2 or the HDM2(1-441) or HDM2(C464A) (0.7 g) mutants and IFIX␣1 or the vector control, pCMV-Tag2B (FLAG) (1.3 g) (Stratagene, La Jolla, CA). Twenty-four hours after transfection, cells were treated with CHX (100 g/ml) for the indicated time, followed by Western blotting using anti-HDM2 or anti-IFIX␣ antibody.
RESULTS

IFIX␣1 downregulates HDM2.
We have previously shown that IFIX␣1 expression is associated with growth inhibition, suppressed transformation, and tumorigenicity (18) . In searching for the mechanism underlying this phenomenon, we found that HDM2 protein levels were greatly reduced in the IFIX␣1-expressing MDA-MB-468 cells (which express the p53 mutant), i.e., X-1 and X-2 (18), compared with those in the vector (Fig. 1A) . To test whether IFIX␣1 expression is the cause for HDM2 reduction, we performed an IFIX␣1 knockdown experiment on a low IFIX␣1 expression cell line, i.e., MDA-MB-468 (X-1). As shown in Fig. 1B , IFIX siRNA, a small inhibitory RNA specific for IFIX (Dharmacon), but not the control siRNA transfection rescued the reduced HDM2 level in MDA-MB-468 (X-1). This result indicates that IFIX␣1 may regulate the level of HDM2. However, IFIX␣1 expression has little effect on the HDM2 mRNA levels (Fig. 1C) . Consistently, HDM2 reduction was also observed in two other cell lines, i.e., H1299 (a human nonsmall cell lung carcinoma cell line) ( Fig.  2B ) and 293 (a human embryonic kidney cell line) (data not shown), in a transient transfection system. These results suggest that IFIX␣1 regulates HDM2 protein, but not mRNA, level.
IFIX␣1 destabilizes HDM2 protein. Next, we wanted to determine whether IFIX␣1 regulates the stability of HDM2. To test this possibility, H1299 cells were cotransfected with HDM2 and FLAG-tagged IFIX␣1 (or the empty FLAG vector), followed by a CHX (a protein synthesis inhibitor)-chase assay. As shown in Fig. 1D and E, the half-life of HDM2 was around 13 min in the presence of exogenous IFIX␣1 but was 23 min in the absence of IFIX␣1. This result suggests that IFIX␣1 enhances the turnover rate of HDM2 in cells.
IFIX␣1 promotes the ubiquitination of HDM2. To determine whether the IFIX␣1-mediated HDM2 destabilization and degradation depends on the proteasome machinery, the IFIX␣1 stable MDA-MB-468 cell lines and the vector control cells were treated with a proteasome inhibitor, MG132. As shown in Fig. 2A , MG132 treatment completely restored the HDM2 level in the IFIX␣1 stable cells compared with no treatment (Fig. 1A) . A similar observation was observed in the MG132-treated H1299 cells transiently transfected with EGFP-IFIX␣1 (Fig. 2B) . These results clearly indicate that proteasome machinery is required for the IFIX␣1-mediated HDM2 downregulation.
Since ubiquitinated proteins are targeted for proteasomemediated degradation (35) and HDM2 is ubiquitinated by its own E3 ubiquitin ligase activity (23, 38) , it is possible that IFIX␣1 may destabilize HDM2 by promoting its ubiquitination. To test this possibility, we determined the effect of IFIX␣1 on the levels of ubiquitinated HDM2. H1299 cells were cotransfected with HDM2, HA-tagged ubiqutin, and increasing amounts of IFIX␣1, followed by IP using anti-HDM2 antibody and Western blotting using anti-HA, anti-HDM2, and anti-IFIX␣ antibodies. As shown in Fig. 2C (left panel), IFIX␣1 increases the levels of ubiquitinated HDM2 in a dosedependent manner. The results obtained from two independent experiments are presented (Fig. 2D) . Interestingly, the presence of IFIX␣1 in the HDM2 immunocomplex suggests that IFIX␣1 interacts with HDM2 ( Fig. 2C , lower panel). The high molecular mass (Ͼ150 kDa) of HDM2 suggests that IFIX␣1 may promote polyubiquitination of HDM2. Since the polyubiquitin chains formed at the lysine (K)-48 residue of ubiquitin are critical for proteasome-mediated proteolysis (10), we cotransfected H1299 cells with HDM2, IFIX␣1, and a myctagged ubiquitin mutant, i.e., Ub-K48R (which is unable to form polyubiquitin chains). As shown in Fig. 2C (right panel), IFIX␣1 failed to induce the high-molecular-weight ubiquitinated HDM2. These results suggest that IFIX␣1 promotes polyubiquitination of HDM2 and are consistent with the observations that IFIX␣1 destabilizes HDM2 through proteasome-mediated degradation ( Fig. 1D and E and 2A and B).
Since HDM2 is the substrate of its own E3 ligase activity (23, 38) , it raises a possibility that IFIX␣1 may destabilize HDM2 through the E3 ligase activity of HDM2. To test this possibility, we first performed a CHX-chase experiment to determine the effect of IFIX␣1 on the turnover rate of the RING finger deletion mutant, i.e., 1-441 (in which E3 ligase domain is deleted) (41) . As expected, the 1-441 mutant is very stable (Fig. 2E , left panel) compared with the wild-type HDM2 (Fig.  1D , left panel). However, IFIX␣1 has no effect on the turnover rate of the 1-441 mutant (Fig. 2E, right panel) . This result suggests that the RING finger domain of HDM2 is required for the IFIX␣1-mediated destabilization. The cysteine residue at position 464 (C464) located in the RING finger domain of HDM2 is important for self-ubiquitination (23, 38) . Therefore, mutation of C464 to alanine (C464A) abolishes the E3 ligase activity of HDM2. To specifically test whether E3 ligase activity is required for IFIX␣1 to destabilize HDM2, we performed a CHX-chase assay to determine the IFIX␣1 effect on the stability of the C464A mutant. As shown in Fig. 2F (left panel), the C464A mutant is relatively stable compared with the wildtype HDM2 (Fig. 1D, left panel) . Importantly, IFIX␣1 has no effect on the turnover rate of C464A mutant (Fig. 2F, right  panel) . These data strongly suggest that the E3 ligase activity is required for the IFIX␣1-mediated HDM2 destabilization and also rule out the possibility that IFIX␣1 may interact with an unknown E3 ligase protein that trans ubiquitinates HDM2. Cell lysates isolated from IFIX␣1 stable MDA-MB-468 cell lines (X-1 and X-2) and the vector control cell lines (V) were analyzed by Western blotting using antibodies against HDM2, p53, IFIX␣, and ␣-tubulin. (B) IFIX␣1 is responsible for HDM2 downregulation. MDA-MB-468 (X-1) cells were transfected with IFIX siRNA (100 nM) or NS siRNA (100 nM). Forty-eight hours after transfection, the expression levels of HDM2, IFIX␣1, p53, and ␣-tubulin were analyzed by Western blotting. (C) IFIX␣1 has little effect on the steady-state mRNA levels of HDM2 in MDA-MB-468 cells. Total RNA (10 g) isolated from the parental MDA-MB-468 (C), the IFIX stable cell lines (X-1 and X-2), and the empty vector transfected cells (V) was analyzed by Northern blotting using HDM2, p53, or IFIX␣1 cDNA as a probe. The 18S and 28S rRNAs are shown as loading controls. (D) IFIX␣1 destabilizes HDM2. H1299 cells were cotransfected with HDM2 (0.7 g) and the empty vector (V) (1.3 g) or FLAG-IFIX␣1 (IFIX␣1) (1.3 g). Twenty-four hours posttransfection, cells were treated with CHX (100 g/ml). Cell lysates were isolated at 0, 15, and 30 min after CHX treatment for Western blotting using antibodies against HDM2, IFIX␣, and ␣-tubulin. A representative experiment is shown. (E) The amount of HDM2 protein at zero time point was arbitrarily set at 100%. The percentage of HDM2 protein remaining was determined using Bio-Rad software. The results obtained from three independent experiments are shown. The increase of the ubiquitinated HDM2 levels (n-fold) was calculated based on two independent experiments using Bio-Rad software. (E and F) The E3 ligase activity is required for the IFIX␣1-mediated HDM2 destabilization. The HDM2(1-441) (E) or HDM2(C464A) (F) (0.7 g) mutant was cotransfected into H1299 cells with the empty vector (V) (1.3 g) or FLAG-IFIX␣1 (IFIX␣1) (1.3 g). CHX-chase assay and Western blotting were carried out as described in the legend to Fig. 1D .
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The IFIX effect on HDM2 and p53 autoregulatory loop. HDM2 and p53 form an autoregulatory loop in which HDM2 destabilizes p53 and p53 activates HDM2 transcription. IFIX␣1 drastically downregulates HDM2 in p53-deficient cells, such as MDA-MB-468, H1299, and 293 ( Fig. 1A and 2B ; data not shown). However, little change in the HDM2 protein levels was observed in IFIX␣1 stable MCF-7 cells (expressing wildtype p53) (Fig. 3A, top panel) . The induction of p53 (Fig. 3A) leads to the increase of HDM2 mRNA levels in these cells (Fig. 3C, top panel) . These results support the notion that IFIX␣1 cross talks with the HDM2-p53 autoregulatory loop by promoting HDM2 degradation, leading to p53 stabilization. The elevated p53 levels, in turn, increase the HDM2 levels. The net result of these two opposing effects may be responsible for the apparent little change in the HDM2 levels in cells expressing IFIX␣1. To further confirm this result, we employed HCT116 (a human colorectal carcinoma cell line) and its p53-null derivative, HCT116(p53 Ϫ/Ϫ ), in which both p53 alleles were deleted by homologous recombination (8) . Both cell lines were transfected with either EGFP-IFIX␣1 or EGFP control vector. Cell lysates isolated from the GFP-positive cells were analyzed by Western blotting. As shown in Fig. 3B (left panel), similar to that observed in the IFIX␣1 stable MCF-7 cells (Fig. 3A) , IFIX␣1 expression increases p53 levels but has little effect on HDM2 levels in HCT116 cells. In contrast, IFIX␣1 expression resulted in a drastic reduction of HDM2 in HCT116(p53 Ϫ/Ϫ ) cells (Fig. 3B, right panel) as observed in other p53-deficient cells (Fig. 1A and 2B) .
IFIX␣1 increases p53 protein stability. IFIX␣1 destabilizes HDM2, resulting in p53 induction in the IFIX␣1 stable MCF-7 cell lines, X-1 and X-2, compared with that in the vector control cells (Fig. 3A) . Importantly, there is no change in the p53 mRNA levels regardless of IFIX␣1 expression (Fig. 3C) , supporting the idea that IFIX␣1 downregulates HDM2, leading to p53 stabilization. Indeed, we show that the p53 protein turnover rate is significantly increased in X-1 and X-2 cells (Ͼ30 min) compared with that in the control cells (Ͻ15 min) (Fig.  3D ). This result is consistent with the idea that IFIX␣1 stabilizes p53 protein by destabilizing HDM2.
The causative effect of IFIX␣1 on p53 induction was further confirmed by an IFIX␣1 knockdown experiment using IFIX siRNA. As shown in Fig. 3E , the IFIX siRNA transfection specifically reduces p53 protein levels in a low-IFIX␣1-expressing MCF-7 cell line, X-1, compared with transfection with the nonspecific scramble control (NS) siRNA. As expected, p53 reduction by IFIX siRNA correlates with decreased expression of a p53 transcriptional target, p21 CIP1 (Fig. 3F) . These results indicate that IFIX␣1 can stabilize and activate p53 in the IFIX␣1 MCF-7 stable cell lines.
IFIX␣1 activates the p53-mediated transcription. IFIX␣1 induces p53 and increases the steady-state mRNA levels of p53 target genes, e.g., the HDM2 gene (Fig. 3C) , and p21 CIP1 (18) expression, suggesting that IFIX␣1 induces p53-mediated transcriptional activity. To test that possibility, we transfected H1299 with PG13-LUC, a luciferase reporter construct containing multiple p53 binding sites (79) , or MG15-LUC, a corresponding construct containing mutated p53 binding sites. Since H1299 is p53 null (86) , it is necessary to cotransfect a p53 expression vector to observe the increase of p53-mediated transcription. We found that IFIX␣1 readily enhanced the p53-mediated transcriptional activity of PG13-LUC (but not MG15-LUC) in a dose-dependent manner (Fig. 4A) . This result indicates that IFIX␣1 indeed activates the p53-mediated transcription. We then tested whether IFIX␣1 also increases p53 DNA binding. We employed a mobility shift assay in which the 32 P-labeled oligonucleotides containing p53 DNA binding sites were incubated with the nuclear extracts isolated from the IFIX␣1 stable MCF-7 cell lines (X-1 and X-2) and the vector control cells. The p53/DNA complex was resolved by a native gel electrophoresis. As shown in Fig. 4B (left panel) , the p53 DNA binding activity is strongly enhanced in X-1 and X-2 cells compared with that in the control cells. The p53 DNA binding activity induced by DNA-damaging agents, such as UV light, serves as a positive control. The protein/DNA complex is p53 specific since incubation with anti-p53 antibody in the X-1 nuclear extract diminishes this complex. The increase of p53 DNA binding correlates well with an increase of p53 in the nuclear extracts isolated from the X-1 and X-2 cells (Fig. 4B,  right panel) .
In keeping with the activation of p53 by IFIX␣1 (Fig. 4A ), we found that IFIX␣1 also activates a luciferase reporter gene driven by a p21 CIP1 promoter (21) in the wild-type p53-expressing cell lines, e.g., MCF-7 and HCT116 (data not shown). The induction of p21 CIP1 promoter activity was similar to that observed with either IFN-␥ (29) or another HIN-200 protein, IFI16 (85) . This result indicates that IFIX␣1 can transcriptionally activate the p21 CIP1 gene. Consistently, IFIX␣1 enhanced the binding of p53 to the endogenous p21 CIP1 promoter in the IFIX␣1 stable MCF-7 cell lines (X-1 and X-2) compared with the basal levels of p53 binding in the vector control cells, using a ChIP assay (Fig. 4C) . These results suggest that IFIX␣1 activates p21 CIP1 transcription by upregulating p53 protein levels and transcriptional activity.
HDM2 downregulation is required for the IFIX␣1-mediated p53 induction and activation. Next, we wanted to determine whether the activation of p53 by IFIX␣1 is through repression of MDM2. To do so, we cotransfected a p53 Ϫ/Ϫ MEF and a p53 Ϫ/Ϫ mdm2 Ϫ/Ϫ DKO MEF with GFP-tagged p53 and increasing amounts of IFIX␣1. The exogenous p53 is induced by IFIX␣1 in the p53 Ϫ/Ϫ MEF in a dose-dependent manner, presumably caused by increasing p53 stability in these cells (Fig. 5A, left panel) . As expected, p53 is more stable in the DKO MEF (Fig. 5A, right panel) . However, IFIX␣1 has no effect on the p53 levels in these cells (Fig. 5A, right panel) . Consistent with these observations, IFIX␣1 activates p53-mediated transcription in a dose-dependent manner in the p53 Ϫ/Ϫ MEF but not in the DKO MEF (Fig. 5B) . Notably, p53 drastically enhances p53-mediated transcription in the DKO MEF in the absence of IFIX␣1. It is likely due to the higher p53 levels in the DKO MEF than those in the p53 Ϫ/Ϫ MEF (Fig.  5A) . Together, these results support the idea that IFIX␣1 induces p53 levels and its transcriptional activity by targeting primarily HDM2.
IFIX␣1 promotes p53 nuclear accumulation. Since nuclear p53 is active in transcriptional activation, it is conceivable that increased p53-mediated transcription should correlate with increased p53 nuclear localization. Indeed, p53 is predominantly nuclear and colocalized with IFIX␣1 in the IFIX␣1 stable MCF-7 cell line, X-2 (data not shown) (18) . To further confirm this observation, we transiently transfected a vector expressing . Forty-eight hours after transfection, the GFP-positive cells were collected using FACS. Cell lysates were analyzed by Western blotting using antibodies against HDM2, p53, IFIX␣, and ␣-tubulin. (C) IFIX␣1 induces the steady-state HDM2 mRNA level but has little effect on p53 mRNA levels in MCF-7 cells. Total RNA (10 g) isolated from the parental MCF-7 (C) and the stable cell lines transfected with the empty vector (V) or IFIX␣1 expression vector (X-1 and X-2) was analyzed by Northern blotting using HDM2, p53, or IFIX␣1 cDNA as a probe. The 18S and 28S rRNAs are shown as loading controls. (D) IFIX␣1 increases p53 protein stability. The IFIX␣1 stable MCF-7 (X-1 and X-2) and the vector control (V) cells were treated with CHX (100 g /ml) for the time indicated. Cell lysates were analyzed for the expression of p53 and ␣-tubulin. (E and F) Depletion of IFIX␣1 reduces p53 and p21 CIP1 expression levels. The IFIX␣1 stable MCF-7 cell line, X-1, was transfected with siRNA specific to IFIX␣ (IFIX) (100 nM) or NS siRNA (100 nM). Forty-eight hours after transfection, the expression levels of p53, IFIX␣1, p21 CIP1 , and ␣-tubulin were analyzed by Western blotting. Fig. 5C , the majority of GFP-p53 is localized in the nuclear compartment of the IFIX␣1 stable cell lines, X-1 and X-2, compared with the vector control cells. These data indicate that IFIX␣1 promotes p53 nuclear localization. Since HDM2 is the target of IFIX␣1 to induce p53 (Fig. 5A) , it is possible that HDM2 may also be the target for the IFIX␣1-mediated p53 nuclear accumulation. To test this possibility, we cotransfected GFP-p53, HDM2 (or the C464A mutant), and IFIX␣1 (or empty vector control) into H1299 (which is p53 null and expresses very low levels of HDM2). Consistent with the results shown in Fig. 5C , IFIX␣1 increases the nuclear localization of p53 in cells transfected with HDM2 compared with empty vector transfection (Fig. 5D ). In contrast, the C464A mutant is sufficient to increase p53 nuclear localization because the C464A mutant is defective in p53 nuclear export (7, 28) . Importantly, IFIX␣1 has no effect on p53 nuclear localization in cells transfected with the C464A mutant (Fig.  5D ). Since IFIX␣1 cannot destabilize the C464A mutant (Fig.  2F ), this result suggests that HDM2 downregulation is required for IFIX␣1 to induce p53 nuclear localization. IFIX␣1 interacts with HDM2. The interaction between IFIX␣1 and HDM2 was detected by a co-IP experiment (Fig.  2C ). To confirm this interaction, 293T cells were transfected with HDM2 and EGFP vector, EGFP-IFIX␣1, or EGFP-IFIX␤1. The protein-protein interaction was examined by IP using anti-HDM2 antibody and followed by Western blotting with either anti-GFP or anti-HDM2 antibody. Clear interactions between HDM2 and IFIX␣1 and between HDM2 and IFIX␤1 were detected (Fig. 6A) . A reciprocal experiment using anti-GFP antibody to pull down EGFP-IFIX␣1 and EGFP-IFIX␤1 further confirmed the presence of these complexes (Fig. 6B) . These data strongly suggest that HDM2 interacts with IFIX␣1 or IFIX␤1. We have attempted to investigate a possible interaction between HDM2 and the smallest IFIX isoform, IFIX␥1 (18) . However, we found that IFIX␥1 could be extracted using only SDS-containing lysis buffer (data not shown). Therefore, it is not feasible to detect such an interaction using the standard IP protocol. The interaction between IFIX␣1 and HDM2 was also observed in cells cotransfected with FLAG-tagged IFIX␣1 and HDM2 into 293T cells (data not shown). Consistently, we also found the interaction between IFIX␣1 and HDM2 in the IFIX␣1 stable MCF-7 cell lines, X-1 and X-2, but not in the vector control cells (Fig. 6C) . Together, these results strongly indicate that IFIX␣1 interacts with HDM2.
The apparent lack of HDM2 reduction by IFIX␣1 or IFIX␤1 transfection in 293T cells compared with the empty vector transfection (Fig. 6A and B) is likely due to the constitutive expression of the HDM2 gene driven by a cytomegalovirus promoter. In essence, it resembles the comparable levels of the endogenous HDM2 in the p53-expressing MCF-7 cell lines with or without IFIX␣1 (Fig. 3A and 6C [right panel] ).
IFIX␣1 binds to amino acid region 150 to 230 of HDM2. To map the HDM2 region binding to IFIX␣1, we cotransfected 293T cells with EGFP-IFIX␣1 and HDM2 mutants, e.g., RING finger deletion (1-441) and deletion of amino acids 150 to 230 deletion (⌬150-230) (Fig. 6G) (41) , followed by IP/ Western blotting. Like the wild-type HDM2 (Fig. 6A-B) , the HDM2(1-441) mutant can readily interact with IFIX␣1 (Fig.  6D) . Since the anti-HDM2 antibody used in IP recognizes that the epitope resides within amino acid region 150 to 230 of HDM2, it is therefore not suitable for immunoprecipitating HDM2(⌬150-230). Instead, we cotransfected 293T cells with either EGFP-IFIX␣1 or FLAG-IFIX␣1 and HDM2 or HDM2(⌬150-230), followed by IP with anti-GFP antibody (Fig. 6E) or anti-FLAG antibody (Fig. 6F) , respectively. The HDM2 and IFIX␣1 interaction serves as a positive control. While the expression levels of HDM2(⌬150-230) and IFIX␣1 are detectable by direct Western blotting, there is no HDM2(⌬150-230) protein present in the IFIX␣1 immunocomplex. This result suggests that amino acid region 150 to 230 of HDM2 is required for IFIX␣1 binding (Fig. 6G) .
The HIN region of IFIX␣1 interacts with HDM2. IFIX␣1 differs from IFIX␤1 at the C-terminal sequence (18) . The observation that both isoforms interact with HDM2 ( Fig. 6A  and B) suggests that the C-terminal sequence of IFIX␣1 is dispensable for HDM2 binding. To map the HDM2 binding domain of IFIX␣1, we generated deletion mutants that express either the N-terminal PYD domain (IFIX-N) or the HIN domain (IFIX-HIN). Although IFIX-N is clearly localized in the nucleus, IFIX-HIN, which lacks the putative nuclear localization signal (NLS) in the N-terminal domain (18) , localizes in both nuclear and cytoplasmic compartments. Howbeit, nuclear localization appears dominant (data not shown). To determine their ability to bind HDM2, we cotransfected 293T cells with HDM2 and EGFP, EGFP-tagged IFIX␣1, IFIX-N, or IFIX-HIN, followed by IP using anti-GFP (Fig. 6H, left panel) or anti-HDM2 (Fig. 6H, right panel) antibody and Western blotting with either anti-HDM2 or anti-GFP antibody. These results show that IFIX-HIN, but not IFIX-N, is sufficient to bind HDM2 (Fig. 6I) .
The HIN domain is sufficient to downregulate HDM2 and induce p53. The observation that IFIX-HIN is sufficient to bind HDM2 (Fig. 6H ) prompted us to test whether IFIX-HIN regulates HDM2 expression. We transfected 293 cells with EGFP-tagged IFIX-HIN or EGFP empty vector, followed by fluorescence-activated cell sorter (FACS) analysis to enrich the GFP-positive cells. The HDM2 protein levels of the GFPpositive cells were analyzed by Western blotting. As shown in Fig. 7A , IFIX-HIN transfection is sufficient to reduce the endogenous HDM2 levels compared to transfection with EGFP without (Ϫ) the anti-p53 antibody (Ab) in the binding reactions to indicate the specific p53/DNA complex (arrow). The nuclear extracts used in the mobility shift assay were analyzed for the expression levels of p53 and IFIX␣1 by Western blotting (right panel). (C) Increased p53 binding to the p21 CIP1 promoter in IFIX␣1 stable cells. A ChIP assay was performed in the vector control (V) and the IFIX␣1 stable MCF-7 (X-1 and X-2) cells. The primer pair that specifically amplifies a 320-bp region of p21 CIP1 promoter was used to analyze the DNA immunoprecipitated by either anti-p53 antibody or a control anti-GFP antibody. The input DNA used for the ChIP assay was likewise amplified to indicate equal loading. Ϫ/Ϫ MEF or DKO MEF was transfected with GFP-p53 (0.1 g) and increasing amounts of IFIX␣1 (0, 1, and 2 g). Twenty-four hours posttransfection, cell lysates were analyzed by Western blotting using antibodies against p53, IFIX␣1, and ␣-tubulin. (B) mdm2 is required for the p53-mediated transcriptional activation by IFIX␣1. PG13-LUC (0.3 g) was cotransfected with p53 (0.01 g) with or without increasing amounts of IFIX␣1 (0.845 g and 1.69 g) into the p53 Ϫ/Ϫ MEF or DKO MEF. pRL-TK (0.05 g) was cotransfected to normalize transfection efficiency. Cells were harvested 24 h after transfection, and the luciferase activity was measured using a dual luciferase assay. The relative luciferase activity was obtained by setting the normalized activity of PG13-LUC alone at 1. (C) IFIX␣1 promotes p53 nuclear localization. GFP-p53 was transfected into the IFIX␣1 stable MCF-7 (X-1 and X-2) and the vector control (V) cells. Twenty-four hours after transfection, the number of cells in which GFP-p53 localized in both nucleus and cytoplasm (CϩN) or predominantly in the nucleus (N) was counted. Average results were obtained from two independent experiments. V (CϩN, 54.55% Ϯ 3.45%; N, 45.45% Ϯ 3.45%); X-1 (CϩN, 36.1% Ϯ 1.9%; N, 63.9% Ϯ 1.9%); and X-2 (CϩN, 21.15% Ϯ 1.85%; N, 78.85% Ϯ 1.85%). (D) IFIX␣1 has little effect on p53 nuclear localization in the presence of the HDM2(C464A) mutant. GFP-p53 (0.25 g) was cotransfected into the H1299 cells with HDM2 (0.75 g) and IFIX␣1 or empty vector (1.25 g). Twenty-four hours after transfection, the number of cells in which GFP-p53 localized in both nucleus and cytoplasm or predominantly in the nucleus was counted. Average results were obtained from two independent experiments: V and HDM2 (CϩN, 49% Ϯ 3.4%; N, 51% Ϯ 3.4%); IFIX␣1 and HDM2 (CϩN, 29% Ϯ 0.4%; N, 71% Ϯ 0.4%); V and C464A (CϩN, 31.7% Ϯ 3.1%; N, 68.3% Ϯ 3.1%); and IFIX␣1 and C464A (CϩN, 27% Ϯ 1.6%; N, 73% Ϯ 1.6%). On average, more than 80 GFP-positive cells were counted in each transfection experiment.
vector. As expected, MG132 treatment stabilizes HDM2 expression. However, unlike those of IFIX␣1 (Fig. 2B) and IFIX-N (data not shown), which are stable proteins, IFIX-HIN expression levels increase with MG132 treatment (Fig. 7A) . This result suggests that IFIX-HIN is a relatively unstable protein and is susceptible to degradation by proteasome machinery.
The observation that IFIX-HIN is sufficient to bind and to downregulate HDM2 suggests that it may be sufficient to induce p53. To test this possibility, we cotransfected H1299 cells with p53 and increasing amounts of IFIX␣1, IFIX-HIN, or IFIX-N. As expected, we observed a dose-dependent increase of p53 in cells transfected with IFIX␣1 (Fig. 7B) . The endogenous p21
CIP1 is also increased in a dose-dependent manner, indicating that the p53-mediated transcription is activated (Fig.  7B) . Interestingly, like IFIX␣1, IFIX-HIN is able to induce both p53 and p21 CIP1 (Fig. 7C) . In contrast, the HDM2 binding-deficient mutant, IFIX-N (Fig. 6H) , has no effect on p53 or p21 CIP1 (Fig. 7D ). This result is further confirmed by a Northern blot analysis in which the p53-induced p21 CIP1 mRNA levels are increased by IFIX␣1 and IFIX-HIN but not IFIX-N (Fig. 7E) . Together, these data suggest that the HIN domain of IFIX␣1 is sufficient to downregulate HDM2, leading to p53 induction, which in turn activates the p53-mediated transcription, e.g., p21
CIP1 . Our previous observation that IFIX␥1, which lacks the HIN domain, was unable to induce p21 CIP1 (18) supports the requirement of the HIN domain for p53 induction.
IFIX mediates the HDM2 downregulation by IFN-␣. IFIX␣1 is an IFN-inducible protein (18) . We tested whether the regulation of HDM2 by IFIX␣1 can be observed in the IFN-inducible system. We then examined the effect of IFN on HDM2 expression in Raji cells (a human Burkitt's lymphoma cell line in which p53 is mutated) (20) because IFIX␣1 expression can be readily induced by IFN-␣ in these cells (18) . Interestingly, we observed a biphasic effect on the HDM2 protein levels in response to the IFN-␣ treatment (Fig. 8A) . In particular, the HDM2 levels gradually increase between 0 and 48 h and decrease sharply at 72 h of treatment. Notably, the endogenous IFIX␣ (which may include ␣1 and ␣2 isoforms) protein expression becomes detectable at 48 h and persists through 72 h of treatment. As a positive control for the IFN-␣ responsiveness, the same membrane was probed with an antibody against a known IFN-inducible protein, PKR (39) . As expected, the PKR levels increase in response to IFN-␣ treatment, indicating that the IFN pathway is activated (Fig. 8A) . This result shows that IFN indeed regulates HDM2 expression. In particular, IFN downregulates HDM2 at 72 h of treatment.
To examine the role of IFIX in the IFN-␣-mediated HDM2 downregulation, we looked for a condition in which IFIX, but not other HIN-200 proteins, e.g., IFI16, MNDA, and AIM2, could be readily induced by IFN-␣. Under the normal condition with 10% FCS, we found that the expression levels of both IFIX␣ and IFI16 are induced by IFN-␣ (Fig. 8B) . The expression of MNDA was not detectable regardless of IFN-␣ treatment (data not shown). The expression of AIM2 is not clear under this condition because the anti-AIM2 antibody is not available. Interestingly, we found that IFIX␣ but not IFI16 could be induced by IFN-␣ in low serum with 0.2% FCS (Fig.  8C, left panel) . Importantly, the IFN-␣-induced IFIX␣ expression remains correlated with HDM2 downregulation under this condition. Thus, the low serum condition provides us a unique opportunity to determine the role of IFIX␣ in IFN-␣-induced HDM2 downregulation. To ensure the specificity of IFIX siRNA, a mixture of four IFIX siRNAs (see Materials and Methods) was transfected into Raji cells, followed by IFN-␣ treatment. We show that IFIX siRNAs transfection reduces IFIX␣ but that it has little effect on IFI16 expression (Fig. 8C, right panel) . Importantly, IFIX␣ knockdown by IFIX siRNAs increases the expression level of HDM2 compared to transfection with NS siRNA (Fig. 8C, right panel) . This result indicates that IFIX␣ plays an essential role in the IFN-␣-mediated HDM2 downregulation.
To test whether the interaction between IFIX␣ and HDM2 also occurs in the IFN-inducible system, we performed IP/ Western blot analysis on Raji cells treated with IFN-␣ for 48 h (at this time point, HDM2 levels are not reduced) (Fig. 8A) . As shown in Fig. 8D , a physiological interaction between IFIX␣ and HDM2 was detected in these cells. The induction of IFIX␣ by IFN-␣ correlates well with an increase of interaction between IFIX␣ and HDM2 (Fig. 8D ).
Discussion
In this report, we present evidence suggesting that IFIX␣1 functions as a negative regulator of HDM2. Consequently, IFIX␣1 positively regulates p53 by stabilizing p53, leading to an increase of p53-dependent transcription and nuclear accumulation. Importantly, these IFIX␣1 effects on p53 require HDM2 downregulation, suggesting that HDM2 is the primary target of IFIX␣1.
IFIX␣1 interacts with HDM2 and promotes its ubiquitination and degradation (Fig. 1, 2, and 6) . The mechanism by which IFIX␣1 promotes HDM2 ubiquitination is not clear. HIN-200 proteins are not known to possess enzymatic activity. It has been postulated that these proteins may function as nuclear scaffolds to modulate gene transcription through interaction with other proteins (12) . Therefore, it is possible that IFIX␣1, when binding to HDM2, may simultaneously compromise the binding of certain HDM2 interacting proteins that negatively regulate the ubiquitination of HDM2, e.g., p14ARF (70, 82) , MDMX (32, 74) , TSG101 (50) , and HAUSP (51) . Thus, it is conceivable that IFIX␣1 may disrupt these interactions and restore the E3 ligase activity of HDM2, resulting in an increase of ubiquitination. In addition, posttranslational modifications, such as sumoylation, acetylation, and phosphorylation, are also known to regulate the E3 ligase activity of HDM2 (9, 58) . It is possible that IFIX␣1 may alter certain modifications of HDM2 and tip the balance to favoring ubiquitination. HDM2 is known to be a nucleocytoplasmic shuttling protein (68) . Moreover, since IFIX␣1 binds to HDM2 through amino acid region 150 to 230, which contains nuclear export signals/NLSs (Fig. 6G) , it is also possible that IFIX␣1 may regulate HDM2 ubiquitination and degradation by altering the cellular localization of HDM2.
Emerging evidence has suggested a cross talk between the IFN signaling pathway and the p53 tumor suppressor pathway. For example, it was shown that IFN-␣/␤ transcriptionally activates p53 (77) . In contrast, certain IFN-inducible proteins were shown to regulate p53 posttranscriptionally. For instance, PKR not only activates p53 transcription (87) but also binds to the C terminus of p53 and phosphorylates serine 392 (14) . In turn, PKR upregulates p53-mediated transcription (13) . IFI16 binds to p53 and augments the p53-mediated transcriptional activation (26, 43) . This interaction between IFI16 and p53 may contribute to the ability of IFI16 to sensitize cells to p53-dependent apoptosis induced by ␥-irradiation (26) . Another example is p202a, which inhibits p53-mediated transcriptional activity by presumably being a component of the p53 protein complex through binding to p53 binding protein 1 (15) . Although IFIX␣1 colocalizes with p53 in the nucleus (data not shown), we have not detected a physical association between IFIX␣1 and p53 despite intensive efforts to look for such interaction (data not shown). Additional experiments, such as gel filtration analysis, are needed to verify this observation. However, it remains possible that the interactions between IFIX␣1 and HDM2 and between p53 and HDM2 may exist as mutually exclusive complexes. If this hypothesis is proven valid, it may suggest that, unlike that between PKR, IFI16, and p202a, the interaction between IFIX␣1 and p53 may not be necessary for the IFIX␣1-induced p53 stabilization and transcriptional activation. Rather, our data suggest that HDM2 but not p53 is the primary target of IFIX␣1. This conclusion is supported by the observation that ectopic p53 can be stabilized and activated by IFIX␣1 only in the p53 Ϫ/Ϫ MEF but not in the DKO MEF ( Fig. 5A and B) .
The nuclear localization of IFIX-N is somewhat expected since a putative NLS, 134 LGPQKRKK, resides within the N- terminal region of IFIX␣1 (18) . However, unlike IFIX␥1, which forms nuclear specks (18) , IFX-N localizes throughout the nucleus (data not shown). This result suggests that the unique C-terminal 52-amino-acid region of IFIX␥1 may be responsible for the nuclear speck localization. On the other hand, the attenuated nuclear localization of IFIX-HIN (data not shown) suggests that the N-terminal NLS is required for the exclusive nuclear localization of IFIX␣1. It also suggests that other NLSs may exist to direct IFIX-HIN to the nucleus. Two highly charged regions, e.g., 259 LKRKFIKKR and 306 RRAKKIPK, reside within the HIN domain and may represent such NLSs. Alternatively, it is possible that IFIX-HIN may be shuttled into the nucleus by interacting with unknown nuclear protein.
We mapped the HDM2 binding region to the HIN domain of IFIX␣1 (Fig. 6H) . Remarkably, like IFIX␣1, IFIX-HIN is sufficient to downregulate HDM2 and to induce p53 and p21 CIP1 ( Fig. 7C and E) . This result is consistent with our previous finding that p21 CIP1 induction was observed in cells expressing IFIX␣1 and IFIX␤1 but not IFIX␥1, which lacks the HIN domain (18) . Thus, the N-terminal PYD domain and the C-terminal sequence of IFIX␣1 appear to be dispensable for downregulating HDM2. It is thus possible that IFIX-HIN may be sufficient to destabilize HDM2. Although experiments have been performed to test this possibility, the instability of IFIX-HIN protein (Fig. 7A) has become a challenge in this effort. Perhaps an exclusively nucleus-localized IFIX-HIN, by tagging its own NLS or a heterologous NLS, may help to solve the stability issue. Nevertheless, given that IFIX-HIN is the signature motif of HIN-200 proteins, it is possible that other HIN-200 family proteins may possess a similar activity to destabilize HDM2.
We have previously shown that IFIX␣1 induced p21 CIP1 in cells with or without wild-type p53 (18) . Although we show in this study that IFIX␣1 induces p21 CIP1 through p53 upregulation ( Fig. 3E and F, 4C , and 7B and E), the p53-independent mechanism remains to be elucidated. Interestingly, recent reports showed that HDM2 can interact directly with p21 CIP1 protein and promotes its degradation (41, 88) . Therefore, one possible p53-independent posttranslational mechanism underlying p21 CIP1 induction may be through HDM2 downregulation by IFIX␣1.
In addition to their role in innate and adaptive immunity (5), IFNs also possess proapoptosis, antiangiogenesis, and antiproliferation activities, which have been the basis for using IFNs to treat human malignancies (34, 69) . The antitumor activity of IFN is likely attributed to the tumor suppressor functions of certain IFN-inducible proteins (34, 48) . HIN-200 genes have been implicated as tumor suppressors due to their loss or reduced expression in certain human malignancies (for recent reviews, see references 2 and 54). IFIX␣1, a novel member of the human HIN-200 gene family, is downregulated in breast cancer, and its expression is associated with growth inhibition and tumor suppression (18) . Here, we present a mechanism for the IFIX␣1-mediated antitumor activity. Our data show that IFIX␣1 destabilizes HDM2. IFIX␣1 does so by binding to HDM2 and promoting its ubiquitination and degradation. Consequently, p53 is stabilized and the p53-responsive gene products, such as p21 CIP1 , are activated, leading to growth inhibition. Therefore, the cross talk between the IFN-IFIX␣1 pathway and the HDM2-p53 pathway may contribute in part to the overall IFN-mediated antitumor activity in certain human cancers.
